TELA Stock Overview
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TELA Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.39 |
| 52 Week High | US$11.26 |
| 52 Week Low | US$4.23 |
| Beta | 0.95 |
| 1 Month Change | -21.04% |
| 3 Month Change | -38.86% |
| 1 Year Change | -53.69% |
| 3 Year Change | -68.00% |
| 5 Year Change | n/a |
| Change since IPO | -67.12% |
Recent News & Updates
Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 24
Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)
Mar 08Recent updates
Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 24Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)
Mar 08TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?
Oct 07Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult
Jul 31TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption
Oct 02Tela Bio prices $32M common stock offering
Aug 16Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?
May 12TELA Bio - Follow Up With Management
Jan 14Our First Look At TELA Bio
Nov 04TELA Bio Plugging Away
Oct 25TELA Bio (TELA) Investor Presentation - Slideshow
May 26Bearish: Analysts Just Cut Their TELA Bio, Inc. (NASDAQ:TELA) Revenue and EPS estimates
Mar 30Health Check: How Prudently Does TELA Bio (NASDAQ:TELA) Use Debt?
Feb 12
TELA Bio guides Q4 and FY20 revenue below consensus
Jan 14TELA Bio EPS misses by $0.09, beats on revenue
Nov 11Shareholder Returns
| TELA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -14.8% | 1.6% | 1.0% |
| 1Y | -53.7% | -1.4% | 21.9% |
Return vs Industry: TELA underperformed the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: TELA underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| TELA volatility | |
|---|---|
| TELA Average Weekly Movement | 7.4% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TELA's share price has been volatile over the past 3 months.
Volatility Over Time: TELA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 227 | Antony Koblish | www.telabio.com |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States.
TELA Bio, Inc. Fundamentals Summary
| TELA fundamental statistics | |
|---|---|
| Market cap | US$108.23m |
| Earnings (TTM) | -US$46.66m |
| Revenue (TTM) | US$58.45m |
1.9x
P/S Ratio-2.3x
P/E RatioIs TELA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TELA income statement (TTM) | |
|---|---|
| Revenue | US$58.45m |
| Cost of Revenue | US$17.96m |
| Gross Profit | US$40.49m |
| Other Expenses | US$87.16m |
| Earnings | -US$46.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -1.89 |
| Gross Margin | 69.27% |
| Net Profit Margin | -79.83% |
| Debt/Equity Ratio | 214.6% |
How did TELA perform over the long term?
See historical performance and comparison